Company intelligence / Profile preview
OncoNano Medicine
Dallas, Texas, United States
- Ownership
- Private
- Employees
- ~25
- Development stage
- Other
01
Overview
Lead imaging agent ONM-100 has shown promising Phase 2 results for intraoperative tumor imaging, correctly identifying all tumors detected by standard of care and additional occult disease in 30% of patients. Therapeutic programs in preclinical and Phase 1 stages demonstrate selective delivery and immune activation.
- Therapeutic areas
- Oncology
- Modalities
- Polymeric micelleSmall moleculeMonoclonal antibody fragmentCytokineTherapeutic vaccineFluorescent dye
- Industry
- Biotech
02
Drug pipeline
12 assets11 more assets in the full pipeline.
Request access →Beyond the preview
Go deeper on OncoNano Medicine.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OncoNano Medicine.